|
Apr 3
|
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 31
|
InspireMD's (NASDAQ:NSPR) investors will be pleased with their solid 110% return over the last year
|
|
Mar 26
|
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
|
|
Mar 7
|
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript
|
|
Mar 6
|
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
|
|
Feb 12
|
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
|
|
Dec 20
|
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
|
|
Dec 6
|
InspireMD's Gary Roubin Acquires 13% More Stock
|
|
Nov 27
|
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
|
|
Nov 7
|
InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript
|
|
Nov 6
|
InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ...
|
|
Nov 6
|
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
Nov 2
|
InspireMD to Participate in Upcoming November Investor Conferences
|
|
Apr 27
|
InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update
|